DEFINING SIGNALING PATHWAYS AND EFFECTIVE COMBINATION THERAPY TO IMPROVE OUTCOMES FOR PATIENTS WITH FGFR2-DRIVEN BILIARY CANCER

$2,297,600FY2022Department of the ArmyDOD

The General Hospital Corporation

Investigators